Harrow, Inc. Operating Lease Cost
Harrow, Inc. (HROW) reported Operating Lease Cost of $250.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2021-11-09
- Harrow, Inc. operating lease, cost for the quarter ending 2021-09-30 was $250.00K.
- Harrow, Inc. operating lease, cost for the quarter ending 2021-06-30 was $251.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month |
|---|---|---|---|
| 2021-09-30 | $250.00K 10-Q · filed 2021-11-09 | $501.00K derived: sum of 2 quarters · filed 2021-11-09 | $752.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $251.00K 10-Q · filed 2021-08-10 | $502.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |